List of Gene Editing/CRISPR Companies in Ireland - 6

Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.

What We Do CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics. The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies. The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target' side effects and reduce the required dose. Why We Do Our founder's father was diagnosed with cancer when she was still a student. She witnessed her father suffering from the side effects of his therapy over years. This life experience defined the goal of her life 'how to make cancer drugs safer and better' to make an impact in oncology and do her bit in the global fight against cancer. CyGenica is the result of her and our team's intense desire to make significant contributions to alleviate this suffering and improve the quality of life of millions of cancer patients. Who We Are We are a team of ambitious academicians and professionals striving to improve patient outcomes worldwide. Our goal is to develop the world's safest molecular carrier for therapeutics delivery and grow as an authentic market leader in enabling the next generation genome editing therapeutics for various life-threatening diseases such as cancer. With an indomitable spirit, we are committed to improve the quality of life of such patients.

ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development. To learn more about acquiring your license, contact us today.

Established in 2009, MyBio is a premium supplier of research products, technology, and expertise. We're at the forefront of innovation, enabling the science that's changing lives for the better. Our clients include a range of life scientists based in research laboratories from a variety of sectors. For Academia As scientists ourselves, we understand the challenges that are faced by researchers every day. From needing that all important reagent as quickly as possible, to having to keep an eye on budget – we can help every step of the way too. Quality & Support Our partners are carefully selected, meaning that the products they produce are of the highest quality. As scientists, we only supply tools and equipment that we would use ourselves. Time is of the essence for a busy researcher, therefore we offer full troubleshooting support for when things are not quite going to plan. For Pharma We are an established supplier of custom products for the pharmaceutical industry, with a team of dedicated scientists experienced in the drug discovery and development process. Using our expertise, we are able to work closely with pharmaceutical companies confidentially, tailoring solutions to their unique problems through our well-established ties with our suppliers. We are able to provide our clients with truly customized products that allow for the efficient conversion of potential API leads into candidates and through to established therapeutic drugs. For Suppliers We are always looking to evolve alongside new partners, and have a proud record of delivering strong growth for our suppliers, owing to our knowledge of our customers’ challenges, and our experience of the market on a national level. MyBio are innovative and ambitious, and we are proud of our reputation as one of Ireland’s most trusted suppliers, helping manufacturers penetrate the market and deliver their trusted innovations to laboratories nationwide.

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

PLANTeDIT uses genome editing tools such as CRISPR/Cas9 RNPs® to create genome edited plants.